Can FH gene-deficient renal cancer be cured?

The treatment of FH gene-deficient renal cancer requires a personalized plan based on the patient's specific situation. Early detection and comprehensive treatment can improve the cure rate. Treatment methods include surgical resection, targeted therapy, and immunotherapy, combined with genetic counseling and regular follow-up.

1. Surgical resection is the main treatment for FH gene-deficient renal cancer, especially for early-stage patients. Radical nephrectomy is a common choice, which completely removes the tumor and surrounding tissue to reduce the risk of recurrence. For some patients, nephron-preserving surgery can also be considered to protect renal function.

2. Targeted therapy plays an important role in FH gene-deficient renal cancer. Inhibitors of vascular endothelial growth factor (VEGF), such as sunitinib, sorafenib, and pazopanib, can inhibit tumor angiogenesis and delay disease progression. These drugs are usually used for patients with advanced or metastatic disease.

3. Immunotherapy has become an important treatment option for FH gene-deficient renal cancer by activating the patient's own immune system to fight tumors. PD-1 inhibitors such as nivolumab and pembrolizumab, and CTLA-4 inhibitors such as ipilimumab can significantly improve patients' survival and quality of life.

4. Genetic counseling is essential for patients with FH gene deletion type renal cancer and their families. Since the disease is related to hereditary leiomyomatosis and renal cell carcinoma syndrome HLRCC, it is recommended that patients undergo genetic testing and their families be screened for early detection and intervention.

5. Regular follow-up is the key to ensuring treatment effectiveness and timely detection of recurrence. Patients should undergo imaging examinations such as CT or MRI, as well as blood and urine tests every 3-6 months to monitor tumor markers and changes in renal function.

The treatment of FH gene-deficient renal cancer requires multidisciplinary collaboration, combining surgery, targeted therapy, immunotherapy and genetic counseling, while focusing on regular follow-up and lifestyle adjustments to improve the cure rate and quality of life of patients. Patients should actively cooperate with doctors in treatment, maintain an optimistic attitude, and strive for the best prognosis.